MedTrace Logo

Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

NCT03225963 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2017-07-24

No results posted yet for this study

Summary

Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.

Conditions

Interventions

RADIATION

Chemoradiation with temozolomide

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Principal Investigators

  • Weir Chiang You, M.D. Ph.D. · The Institutional Review Board of Taichung Veterans General Hospital

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-01
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03225963 on ClinicalTrials.gov